BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/30/2021 8:56:50 AM | Browse: 315 | Download: 557
 |
Received |
|
2020-10-27 03:07 |
|
Peer-Review Started |
|
2020-10-22 00:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-12-13 20:04 |
|
Revised |
|
2020-12-26 03:16 |
|
Second Decision |
|
2021-02-04 08:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-02-04 19:06 |
|
Articles in Press |
|
2021-02-04 19:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-02-09 00:55 |
|
Typeset the Manuscript |
|
2021-03-21 09:29 |
|
Publish the Manuscript Online |
|
2021-03-30 08:56 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Case Report |
| Article Title |
Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing-Tao Gao, Li Xie, Li-Ping Ma, Wei Shu, Li-Jie Zhang, Yu-Jia Ning, Shi-Heng Xie, Yu-Hong Liu and Meng-Qiu Gao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meng-Qiu Gao, MD, PhD, Director, Doctor, Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China. gaomengqiu@bjxkyy.cn |
| Key Words |
Pulmonary tuberculosis; Bedaquiline; Extensively drug-resistant tuberculosis; Case report; Tuberculosis |
| Core Tip |
Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis (XDR-TB). Many patients cannot achieve better clinical improvement after bedaquiline is stopped at 24-wk. However, there is no recommendation or guideline on bedaquiline administration beyond 24 wk, which is an important consideration when balancing the benefit of prognosis for XDR-TB against the uncertain safety concerning the newer antibiotics. In the two patients reported here, the longer regimen, including 36-wk bedaquiline treatment, might be an option for patients with XDR-TB. More studies are needed on exploring the effectiveness and safety of prolonged use of bedaquiline for 36 wk vs standard 24 wk in the treatment of multidrug-resistant/XDR-TB, or further exploring the biomarker and criteria indicative for extension of bedaquline to facilitate clinical use of this novel drug. |
| Publish Date |
2021-03-30 08:56 |
| Citation |
Gao JT, Xie L, Ma LP, Shu W, Zhang LJ, Ning YJ, Xie SH, Liu YH, Gao MQ. Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports. World J Clin Cases 2021; 9(10): 2326-2333 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i10/2326.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i10.2326 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
